VYNE Therapeutics Completes Enrollment in Phase IIa Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. announced the completion of enrollment in the Phase IIa study of FMX114 for the treatment of mild-to-moderate atopic dermatitis.
[British Journal of Pharmacology] In vivo, investigators studied the role of Caspase-11 in several angiogenesis mouse models using Caspase-11 wild-type and knockout mice. In vitro, scientists detected the effects of Caspase-4 on endothelial functions and Notch signaling by depleting or overexpressing Caspase-4 in HUVECs.
[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified the reversible SUMOylation of FGF receptor 1 (FGFR1) as an intrinsic fine-tuned mechanism in coordinating endothelial angiogenic signaling during neovascularization.